Figure 4 | Oncogenesis

Figure 4

From: Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer

Figure 4

Dual targeting of ErbB-2/ErbB-3 delays tumor growth of PC cells in nude mice. (a, b) Tumor growth was assessed as described in Materials and methods. Mice harboring tumors were treated with EV20, trastuzumab or their combination (10 mg/kg of each antibody) twice a week. *P<0.05; **P<0.001. In the table (a) the number of complete remissions (CR) and non-responders (NR) tumors in each treatment arm are indicated. CR indicates no longer palpable tumors. NR indicates tumors with growth curves similar to control.

Back to article page